Publication:

Amplification of Chromosomal Segment 4q12 in Non-Small Cell Lung Cancer

Loading...
Thumbnail Image

Date

2009-11-01

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Informa UK Limited
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Ramos, Alex H., Amit Dutt, Craig Mermel, Sven Perner, Jeonghee Cho, Christopher J. LaFargue, Laura A. Johnson et al. "Amplification of Chromosomal Segment 4q12 in Non-Small Cell Lung Cancer." Cancer Biology and Therapy 8, no. 21 (2009): 2042-2050. DOI: 10.4161/cbt.8.21.9764

Abstract

In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3–7% of lung adenocarcinomas and 8–10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFRα activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFRα/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRα/KIT inhibitors.

Description

Research Data

Keywords

Research Subject Categories::MEDICINE::Morphology, cell biology, pathology::Pathology::Molecular medicine, Research Subject Categories::MEDICINE::Surgery::Oncology, Research Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological research::Pharmacology

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories